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Abstract
Background: To explore the strengths and weaknesses of conventional biomedical research
strategies and methods as applied to complementary and alternative medicine (CAM), and to
suggest a new research framework for assessing these treatment modalities.
Discussion: There appears to be a gap between published studies showing little or no efficacy of
CAM, and reports of substantial clinical benefit from patients and CAM practitioners. This "gap"
might be partially due to the current focus on placebo-controlled randomized trials, which are
appropriately designed to answer questions about the efficacy and safety of pharmaceutical agents.
In an attempt to fit this assessment strategy, complex CAM treatment approaches have been
dissected into standardized and often simplified treatment methods, and outcomes have been
limited.
Unlike conventional medicine, CAM has no regulatory or financial gatekeeper controlling their
therapeutic "agents" before they are marketed. Treatments may thus be in widespread use before
researchers know of their existence. In addition, the treatments are often provided as an integrated
'whole system' of care, without careful consideration of the safety issue.
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We propose a five-phase strategy for assessing CAM built on the acknowledgement of the inherent,
unique aspects of CAM treatments and their regulatory status in most Western countries. These
phases comprise:





Summary: Using the proposed strategy will generate evidence relevant to clinical practice, while
acknowledging the absence of regulatory and financial gatekeepers for CAM. It will also emphasize
the important but subtle differences between CAM and conventional medical practice.
Background
The use of complementary and alternative medicine
(CAM) has increased considerably in Western industrial-
ized nations over the last 25 years. In the USA, the expend-
iture is approximately $30 billion per annum, surpassing
current out-of-pocket expenditures for conventional treat-
ments by primary care physicians [1,2]. CAM treatment
modalities include a variety of approaches (i.e., acupunc-
ture, homeopathy, herbal medicine, massage, reflexology,
Reiki healing etc.), many of them based on theories that
differ markedly from conventional Western biomedicine.
The assessment and management of illness often includes
a more detailed interest in patients' wellbeing, as well as
recommendations concerning lifestyle and their quality of
life as a whole [3].
Patients are selective in their choice of CAM treatments
[4], usually abstaining from exclusive use of CAM in acute
life-threatening conditions. Rather, CAM is mainly used
in addition to conventional care for chronic and some
acute health conditions, for disease prevention and for
maintaining wellness. For example, more than half of all
breast cancer patients use some form of CAM complemen-
tary to conventional medicine, most often with a pallia-
tive intent [5,6].
Many physicians do not understand why large segments
of their patients use CAM when research generally has
failed to provide decisive evidence of efficacy. Patients
seem to make these treatment choices based on the qual-
ities of the provider, desire for "individualized" treat-
ments, and their perception of overall effectiveness rather
than efficacy [7-11].
There is apparently a "gap" between the results of rand-
omized controlled trials (RCT) showing little or no effect
and the widespread use and reports of beneficial out-
comes of CAM treatment [12,13]. If we were to assume
that patients are not completely misguided, then we
would need to look closely at the research strategies uti-
lized in the CAM field and try to understand the reasons
for the gap.
The purpose of this paper is therefore to
1. Explore the strengths and weaknesses of conventional
biomedical research strategies and methods as applied to
CAM
2. Suggest a new research framework for assessing these
treatment modalities.
Discussion
Gatekeeping and regulating the use of CAM interventions
A majority of CAM research to date has used the research
strategy employed and developed by clinical pharmacolo-
gists to document, in a prescribed sequential pattern, the
quality, dose, safety, efficacy, and eventual effectiveness of
a drug prior to its general release. In this model, govern-
mental regulatory offices (e.g., USA: FDA, EU: EMEA) act
as gatekeepers. Health insurers, including governmental
single-payer funders, only reimburse for drugs meeting
the appropriate criteria. An important principle in this
research-regulatory-utilization model is that research
determines which drugs are approved for generalized clin-
ical use and are paid for by health insurers. There is also a
growing network of international Health Technology
Assessment Boards that seek consensus about the use of
medical procedures, and some suggest this approach
should be extended to the area of diagnostic tests [14].
Previously, CAM researchers have largely assumed that
these same pharmacological research methods and regu-
latory-reimbursement models can be followed in the eval-
uation of CAM. Much to the frustration of many clinical
researchers, the availability of CAM treatments which are
affordable with little or no reimbursement, however, does
not seem to be amenable to the same rules as those we
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seek to apply to conventional medicine. Even if studies
show that a CAM treatment has no effect, it does not nec-
essarily disappear from the marketplace. We suggest that
this is because the CAM market has had no statutory body
(gatekeeper) that ensured the quality, safety, efficacy and
effectiveness of CAM treatments before they appear on the
"market". Further, since few health insurers reimburse for
CAM treatments, there are few financial gatekeepers. Mil-
lions of patients in developed countries have experienced
the effect of CAM treatments provided in contrast to, or
more likely in addition to, the care they have received in
conventional medicine [15-19]. The situation is thereby
characterized by widespread patient experience of treat-
ment outcomes combined with little research and no reg-
ulatory or financial gate-keeping activity.
Why is a different research strategy needed?
In conventional medicine we rarely question the efficacy
or effectiveness of the overall therapeutic approach to the
treatment of sick people. We take for granted that seeking
advice from a health care professional is a good way of
dealing with diverse health problems. Research in conven-
tional medicine therefore focuses on choosing the best
tools for health professionals to use. These tools include
drugs, diagnostic methods, and surgical procedures, and
employ a methodology often resulting in a one-size-fits-
all therapeutic prescription. Conventional research may,
however, have overlooked that the clinical effect of most
therapies are overestimated when studied under optimal
circumstances on susceptible, cooperative patients.
Despite this, the randomized controlled trial is an impor-
tant method when making decisions about tools to
include in the toolbox of conventional medicine.
Because "conventional" researchers have done most of the
CAM research, it is not surprising that CAM research has
traveled down the same path as conventional medicine. It
has tested the specific efficacy of what conventional
researchers believe to be the active components of a ther-
apy, often discounting synergistic effects. In addition to
providing a predominantly individualistic treatment
approach, many CAM therapists hold that CAM treat-
ments cannot be split up into parts that can be investi-
gated separately. They argue that the total effect adds up to
more than the sum of its parts.
If CAM is to be evaluated comprehensively, one needs to
extend the research focus to all aspects of the treatment
approach [20]. To study only the specific effect of nee-
dling in acupuncture isolated from other interventions
initiated by the acupuncturist, or the effect of a single, iso-
lated homeopathic remedy separated from other aspects
of homeopathic practice, is to neglect other potentially
important components of these interventions [21-25].
Furthermore, clinical research teams should only venture
into this area with a thorough contextual and philosoph-
ical understanding of the CAM treatment paradigm and
its clinical use. Plunging into studies of efficacy that
involve isolated detailed components of a treatment
approach without thoroughly understanding its context is
destined to failure and irrelevance no matter what the
results show. These issues point to the need for a different,
and more complex, research strategy for the CAM field.
A suggested research strategy
The most important unique characteristics of CAM are the
absence of gatekeepers and the complexity of individually
tailored treatments. Our proposed strategy does not con-
tain new methodological elements, but organizes existing
elements in a way that is tailored to pragmatic clinical
practice (Figure 1). The strategy is not meant as a strictly
chronological sequence defining when specific research
phases should occur, but as a framework to guide CAM
research, illustrating the necessary building blocks
required for a rigorous evidence base.
Although we have developed this strategy within a CAM
context, it is appropriate for any treatment approach that
has developed in and from clinical practice, and whose
specific treatment tools are unregulated. In conventional
medicine this might include nursing, health psychology,
counseling and some aspects of general practice. These
areas struggle, as does CAM, to establish a rigorous
research framework around which their research efforts
can be organized [26-28].
Research strategies in drug trials and CAM (proposed)Figure 1
Research strategies in drug trials and CAM (pro-
posed). Phases that contrast the proposed phased research 
strategy in CAM (dark arrows) with that conventionally used 
in drug trials (light arrows).
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Phase1: Context, paradigms, philosophical understanding 
and utilization (What is going on?)
The cornerstone of the suggested research strategy is to
understand the process and assumptions within a particu-
lar therapy, often using an inductive research approach
[29-34]. Researchers need to understand what the treat-
ment procedure is, how many variations there are, what
philosophical foundations underlie it, its ideas about
health and disease, its contextual framework and key
treatment components. They also need to know how
many and what segments of the patient population use it,
and for what conditions. Many research questions can be
asked within phase I, including perceived benefit of the
treatment, cost of treatment, qualifications of the provid-
ers etc.
Phase 2: Safety status (Is it safe?)
Safety issues are important in the treatment of any illness,
but in the area of CAM they cannot be emphasized
strongly enough. The inherent risks of the diseases or ill-
nesses for which patients seek CAM are generally low. The
treatments given should therefore carry a low risk of
adverse effects. CAM treatments have often been claimed
to be without risk, but adverse effects in CAM are more
than occasional case reports. [35]. The methods of choice
to study safety would be similar to the detection of
adverse events associated with pharmaceutical treatments.
The field of acupuncture has provided a thorough and rig-
orous risk assessment [36-39] based on these principles
and the other fields within CAM need to follow suit [40-
42].
Phase 3: Comparative effectiveness (What is the system 
effectiveness?)
Patients are seeking CAM as a treatment system. Research
needs to examine the outcomes of these treatments both
in combination with, and as alternative, to conventional
care. Thus randomized, controlled pragmatic trials are
needed [43,44], wherein the specifics of the system are not
disassembled, but the system under study is allowed to
function as it is clinically practiced, including the urgently
needed evaluation of cost-effectiveness [45]. The prag-
matic trial design has been used in the study of acupunc-
ture treatment of chronic pain [46], and the methodology
is also widely used in conventional medicine, for example
in dietary intervention studies such as the Women's
Health Initiative [47]. In these trials, patients are ran-
domly assigned to treatment alternatives which may
include alternative viable whole systems, conventional
treatment or no treatment. The trials may also evaluate
whole system interventions that are implemented under
protocols that specify individualized treatments based on
specific patient characteristics, following the patterns of
care found in the community. While blinding of the treat-
ment providers and patients/subjects with regard to treat-
ment allocation is usually not feasible, blinding of the
outcomes evaluators can ensure an unbiased comparison
of the outcome assessment.
In conventional medicine, a treatment's efficacy is often
determined before assessment of its effectiveness. It is
considered unethical to include non-efficacious treat-
ments in the real world treatment of patients. Patients are,
however, already using CAM treatments and thus effec-
tiveness studies can be used to guide decisions about the
necessity of studying the efficacy of specific components.
Researchers have voiced this view in several countries over
the last few years [20,48,49]. It was even emphasized in
the much-criticized recent meta-analysis of homeopathy
[50]: "Clearly, rather than doing further placebo-control-
led trials of homoeopathy, future research efforts should
focus on the nature of context effects and on the place of
homoeopathy in health-care systems".
Included in this phase, and bordering on the next phase
would be studies to evaluate how limited a whole package
of care can be while still retaining its overall effectiveness
("Occam's razor"). There are many components within a
CAM treatment approach, but are there any that we can
eliminate and at the same time retain or improve overall
treatment effectiveness?
Phase 4: Component efficacy (What is the efficacy of a 
specific component of the therapy?)
This is the area that has received most attention and
research money to date, and while it is important, it is not
the starting point in our model. The methods of choice are
often double-blind randomized controlled trials. The
well-established documentation of acupuncture/acupres-
sure stimulation of one acupuncture point in the treat-
ment of chemotherapy-induced nausea/vomiting is such
an example [51]. It is, however, important to recognize
that results from such research cannot be used to docu-
ment or disprove the effectiveness of a "whole system"
treatment.
Phase 5: Biological mechanisms (How can treatment 
outcomes be explained biologically?)
We want, and need, to understand the pathways and
mechanisms through which treatments exercise their
influence [52]. This has been and is being explored for
acupuncture as an anti-emetic [53]. We must however
realize that treatment outcomes, both at the system and
component level, can be documented before the biologic
mechanisms are understood, as has been the case for sev-
eral non-surgical conventional therapies. The most prom-
inent example from conventional medicine is probably
aspirin. The anti-inflammatory and pain-killing proper-
ties of aspirin were discovered long before it became
known that aspirin influences prostaglandin synthesis.
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Summary
CAM is not simply a new array of therapeutic tools that
need to be evaluated; it presents other ways to think about
disease and therapeutics, and consequently new ideas
about how research should be strategically developed. In
this article we have suggested two ways of taking this for-
ward. First, the absence of statutory and financial gate-
keepers for CAM presents several issues that need to be
considered closely. Secondly, the structure of CAM
research should be different, in subtle but important
ways. We have provided some suggestions as to how this
alternative research strategy could be structured keeping
in mind that the ultimate goal for all approaches to treat-
ment is to provide effective medical interventions at rea-
sonable cost and without harm.
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